EPIRUS Biopharmaceuticals to Host Biosimilar Key Opinion

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
EPIRUS Biopharmaceuticals to Host Biosimilar Key Opinion Leader Meeting and Webcast on March 30

BOSTON, March 25, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS ), a Boston-based biopharmaceutical company focused on the global development of biosimilar monoclonal antibodies, today announced that it will host a Key Opinion Leader (KOL) breakfast in New York City focused on offering insights into the evolution of the U.S. regulatory landscape, along with a clinician's perspective on the approval and use of biosimilars. The event and live webcast will take place on Monday, March 30, 2015 from 8:00 to 9:15 a.m. Eastern Time.

The meeting will feature a keynote presentation by Jonathan Kay, MD, Professor of Medicine at the University of Massachusetts Medical School and Director of Clinical Research in the Division of Rheumatology at UMass Memorial Medical Center in Worcester, MA. Both Dr. Kay and members of EPIRUS' management team will be available for questions.

To reserve a place, please contact Veronica Molina at 1-212-915-2567 or via email at vmolina@lifesciadvisors.com . A live webcast and subsequent replay of the event will also be available at EPIRUS' website at http://ir.epirusbiopharma.com/index.cfm . The webcast will be archived on the Company's website for a period of three months. This event is limited to institutional investors and sell-side analysts.

Over the past two decades, Dr. Kay's research has focused on clinical aspects and treatment of rheumatoid arthritis and other forms of inflammatory arthritis, as well as on rheumatologic problems of patients with chronic kidney disease. He has been a principal investigator on over 50 clinical trials of novel therapies for rheumatoid arthritis, osteoarthritis, gout and spondyloarthropathies, such as ankylosing spondylitis. More recently, he has been involved in the development of biosimilars to treat rheumatic diseases. Dr. Kay was a member of the group that developed the 2010 ACR/EULAR Diagnostic and Classification Criteria for Rheumatoid Arthritis. He chairs the Rheumatology Working Group and is a member of the Internal Medicine and Musculoskeletal Topic Advisory Groups for the WHO in its Revision of the International Classification of Diseases (ICD)-11.

About EPIRUS Biopharmaceuticals

EPIRUS Biopharmaceuticals (Nasdaq: EPRS ) is a global biosimilar company focused on improving patient access to important medicines. EPIRUS' operationally synergistic pipeline of biosimilar product candidates includes BOW015 (infliximab), BOW050 (adalimumab) and BOW070 (tocilizumab). The reference products for these candidates -- Remicade®, Humira® and Actemra®, respectively -- together generated over $20 billion in global sales for 2013, according to EvaluatePharma®. EPIRUS has developed distinct strategies to access its targeted markets with the goal to build a profitable and sustainable biosimilar business. For more information visit EPIRUS' website at www.epirusbiopharma.com .

Remicade is a registered trademark of Johnson and Johnson ( www.jnj.com )

Humira is a registered trademark of AbbVie ( www.abbvie.com )

Actemra is a registered trademark of Chugai Seiyaku Kabushiki Kaisha Corp., a member of the Roche Group ( www.gene.com )

EPIRUS Biopharmaceuticals, Inc. Jennifer Almond, +1-617-606-3288

Scroll down for more posts ▼

Top 10 Most Recent News Articles

S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
Payoneer Gets OCC Nod, but the Finish Line Is Ahead

Updated Category News Views 121

Federal bank paperwork is not usually thrilling, yet Payoneer just found a potentially meaningful lever for its cross-border payments machine. The company received preliminary conditional approval from the Office of the Comptroller of the Currency to form PAYO Digital Bank, a national trust bank intended to support stablecoin services. That is a real regulatory milestone...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 29

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 91

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 69

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 83

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 130

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
KidneyVoter Push Turns Patient Frustration Into Clout

Updated Category News Views 313

A ballot registration drive rarely tells the whole story, but it can reveal where the pressure is building. The American Association of Kidney Patients says its 2026 nonpartisan KidneyVoter™ effort, “50 States in 50 Days,” reached constituencies in every state after launching September 14. That does not produce a clean vote total or prove legislators will suddenly...

Continue Reading
Pinnacol’s Community Work Earns Denver Chamber Recognition

Updated Category News Views 67

A workers’ comp insurer usually becomes visible on somebody’s worst day; Pinnacol Assurance is being recognized for the work it keeps doing around those days. The Denver Metro Chamber of Commerce has given the Colorado-based, member-owned carrier its 2026 Business Impact Award for Corporate Social Responsibility. Awards can be cheap applause, frankly. This one...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Lives with Sober.Buzz: Embrace the $BUZZ Journey

Updated Category News Views 568

Welcome to Sober.Buzz and the Journey of Transformation Sober.Buzz introduces the Sober Token, known for its symbol $BUZZ, representing a promising initiative aimed at creating a supportive and empowering global community for individuals in recovery from addiction. Designed by those who understand the struggles, the project offers hope and encouragement for those seeking...

Continue Reading
Revolutionizing Ecommerce with Artifi's AI Product Setup Tool

Updated Category News Views 188

Introduction to Artifi's New AI Feature Artifi, a dynamic player in SaaS solutions for product customization, has announced a groundbreaking new feature known as AI Automated Product Setup. This innovative tool aims to drastically reduce setup times, allowing suppliers to efficiently prepare their product data for ecommerce platforms. Understanding the Setup Process The...

Continue Reading
Cleeng Pro: Revolutionizing D2C Subscription Management Today

Updated Category News Views 180

Cleeng Pro: An Innovative Platform for D2C Subscriptions Cleeng, a leader in Subscriber Retention Management, has recently introduced Cleeng Pro, a groundbreaking direct-to-consumer (D2C) subscription platform. This platform empowers creators, developers, and entrepreneurs to establish their subscription services with remarkable efficiency, all without any cost for their...

Continue Reading
SciBase's Nevisense Device Sold to NIH: A New Era in Dermatology

Updated Category News Views 255

SciBase Holding AB hit the headlines back in 2024 when it announced the sale of its flagship device, Nevisense, to the National Institutes of Health (NIH). Traders were buzzing, not just because SciBase is known for its cutting-edge dermatology tech, but because this sale signaled a massive leap into uncharted territory regarding skin health. The NIH isn't just any buyer;...

Continue Reading
FLUENT Launches Innovative MOODS Black in the Sunshine State

Updated Category News Views 262

FLUENT Launches Innovative MOODS Black in the Sunshine State FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF), a leading national cannabis company, is thrilled to announce the exciting launch of its latest product, MOODS Black. This new addition to the well-regarded MOODS lineup showcases high-potency cannabis oil infused with cannabis-derived terpenes, ensuring a superior and...

Continue Reading